Allergic Rhinitis Clinical Trial
Official title:
Cross-over Study of the Impact of Purotex Covers on the Concentration of House Dust Mite Allergen in Bedding and the Quality of Life in Patients With Allergic Rhinitis to House Dust Mite.
Product information:
Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected
for their ability to clean up house dust mite allergen along with other allergen types.
Study design:
- Placebo-controlled: the effect of the Purotex impregnated mattress and pillow covers
will be compared to untreated, classical bedding covers (placebo).
- Cross-over design: There will be 2 'treatment' arms. One arm (Arm 1) in which the
subjects will first use the Purotex impregnated covers (Set A=Purotex) during 2 months
(=period A) and, after a wash out period of 1 month, the untreated covers (set
B=placebo) during 2 months (=period B). In the second arm (Arm 2), the subjects will
first use the untreated set (set A=placebo) and, after a wash out period the Purotex
impregnated covers (set B=Purotex).
- Randomized: The subjects will be randomly assigned to one of the 2 treatment arms.
- Double blind: both the subjects and the investigators will not know to which treatment
arm the subjects are assigned.
Study hypothesis:
We want to investigate:
- if there is a reduced concentration of HDM allergen in Purotex covers compared to
untreated covers in real life
- if patients with allergic rhinitis to house dust mite use the Purotex covers, they
experience an improvement of their quality of life and sleep, and an improvement of
their allergic symptoms and global discomfort
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
| Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
| Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
| Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
| Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
| Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
| Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
| Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
| Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
| Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
| Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
| Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 |